New hope for tough colorectal cancer? drug combo tested in Late-Stage trial

NCT ID NCT05600309

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a new drug combination, MK-4280A (favezelimab plus pembrolizumab), against standard treatments (regorafenib or TAS-102) in 94 Chinese adults with advanced, PD-L1 positive colorectal cancer that has worsened after prior therapy. The main goal is to see if the new combo helps people live longer. The study is completed, and results are pending.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: favezelimab/pembrolizumab (MK-4280A)
What this could lead to: If successful, this could offer a new treatment option for people with advanced colorectal cancer that has not responded to prior therapy.
What could go wrong: This is a relatively small, China-only extension study. The experimental drug may not prove more effective than current treatments and could cause side effects like immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Show contact details

Locations

Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 1185)

Wuxi, Jiangsu, 214122, China
Changzhou Cancer Hospital-Department of Oncology ( Site 1183)

Changzhou, Jiangsu, 213000, China
Chongqing Cancer Hospital ( Site 1151)

Chongqing, Chongqing Municipality, 400030, China
Fudan University Shanghai Cancer Center ( Site 1176)

Shanghai, Shanghai Municipality, 201321, China
Fujian Province Cancer Hospital ( Site 1178)

Fuzhou, Fujian, 350014, China
Guangxi Medical University Affiliated Tumor Hospital ( Site 1158)

Nanning, Guangxi, 531021, China
Hainan General Hospital ( Site 1177)

Haikou, Hainan, 570311, China
Hubei Cancer Hospital ( Site 1152)

Wuhan, Hubei, 430079, China
Hunan Cancer Hospital ( Site 1174)

Changsha, Hunan, 410013, China
Jilin Cancer Hospital ( Site 1163)

Changchun, Jilin, 130012, China
Jinan Central Hospital ( Site 1167)

Jinan, Shandong, 250000, China
Shanghai Tenth People's Hospital ( Site 1170)

Shanghai, Shanghai Municipality, 200072, China
Sir Run Run Shaw Hospital-Medical Oncology ( Site 1173)

Hangzhou, Zhejiang, 310018, China
Southern Medical University Nanfang Hospital ( Site 1154)

Guangzhou, Guangdong, 510515, China
Sun Yat-Sen University Cancer Center ( Site 1150)

Guangzhou, Guangdong, 510060, China
The Second Affiliated Hospital of Anhui Medical University ( Site 1179)

Hefei, Anhui, 230601, China
The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159)

Guangzhou, Guangdong, 510655, China
The Third Xiangya Hospital of Central South University ( Site 1175)

Changsha, Hunan, 410013, China
Tianjin Medical University Cancer Institute and Hospital ( Site 1161)

Tianjin, Tianjin Municipality, 300060, China
West China Hospital Sichuan University ( Site 1172)

Chengdu, Sichuan, 332001, China
Wuhan Union Hospital Cancer Center ( Site 1162)

Wuhan, Hubei, 430022, China
Xiangya Hospital Central South University ( Site 1171)

Changsha, Hunan, 410008, China
Yunnan Province Cancer Hospital-Colorectal surgery ( Site 1169)

Kunming, Yunnan, 650106, China
Zhejiang Cancer Hospital ( Site 1180)

Hangzhou, Zhejiang, 310005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.